Year 2024 / Volume 116 / Number 1
Letter
Hepatitis B virus reactivation after ibrutinib treatment

43

DOI: 10.17235/reed.2023.9587/2023

Carlos Alventosa Mateu, Juan José Urquijo Ponce, Armando Mena Durán, Mercedes Latorre Sánchez, Inmaculada Castelló Miralles, Mariano Linares García, Moisés Diago,

Abstract
New immunosuppressive and antineoplastic drugs are becoming both more numerous and more widely used, even during several years. Most of them present a low-moderate risk of hepatitis B virus (HBV) reactivation in HBsAg-negative and anti-HBc-positive patients. However, their reactivation capacity has not been clearly studied. We present the clinical case of a patient with these serological characteristics who, after 5 years of treatment with ibrutinib for chronic lymphocytic leukaemia, developed VHB reactivation, which was controlled with tenofovir. The occurrence of this event with drugs such as ibrutinib may lead to changes in HBV reactivation prophylaxis.
Share Button
New comment
Comments
No comments for this article
References
1. Rodríguez M, Buti M, Esteban R, Lens S, Prieto M, Suárez E, et al. Consensus document of the Spanish Association for Study of the Liver on the treatment of hepatitis B virus infection (2020). Gastroenterol Hepatol. 2020 Nov 1;43(9):559–87.
2. Innocenti I, Morelli F, Autore F, Corbingi A, Pasquale R, Sorà F, et al. HBV reactivation in CLL patients with occult HBV infection treated with ibrutinib without viral prophylaxis. Leuk Lymphoma. 2019 Apr 16;60(5):1340–2.
3. Innocenti I, Reda G, Visentin A, Coscia M, Motta M, Murru R, et al. Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study. Haematologica. 2022 Jun 1;107(6):1470–3.
4. Herishanu Y, Katchman H, Polliack A. Severe hepatitis B virus reactivation related to ibrutinib monotherapy. Ann Hematol. 2017 Apr 5;96(4):689–90.
5. Tjønnfjord SKV, Tjønnfjord EB, Konopski Z, Tjønnfjord GE. Successful Control of Hepatitis B Virus Reactivation following Restart of Ibrutinib in Chronic Lymphocytic Leukaemia. Case Rep Hematol. 2021 Oct 21;2021:1862446.
Related articles

Letter

Fatal HBV-liver failure after withdrawal of antiviral treatment

DOI: 10.17235/reed.2024.10115/2023

Citation tools
Alventosa Mateu C, Urquijo Ponce J, Mena Durán A, Latorre Sánchez M, Castelló Miralles I, Linares García M, et all. Hepatitis B virus reactivation after ibrutinib treatment. 9587/2023


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 1038 visits.
This article has been downloaded 86 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 09/03/2023

Accepted: 13/03/2023

Online First: 19/04/2023

Published: 11/01/2024

Article Online First time: 41 days

Article editing time: 308 days


Share
This article hasn't been rated yet.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2023 y Creative Commons. The Spanish Journal of Gastroenterology